Impact of pharmaceutical care on drug-related problems in bipolar patients initially treated with lamotrigine
Article Sidebar
Main Article Content
Abstract
This study evaluated the effect of pharmaceutical care for bipolar patients who had just received lamotrigine for the first time. The outcomes were the occurrence of drug-related problems and rash. Methods: The study was a prospective randomized controlled trial of bipolar outpatients in Srithanya Hospita and the patients were treated with lamotrigine for the first time between 5th April and November 30th, 2018. Participants were allocated into a controlled group (the standard service) and a studied group (pharmaceutical care). Drug-related problems were evaluated before and after taking lamotrigine for 8 – 12 weeks. Results: There were 117 patients who attended the study and the average age ± SD was 32.0 ± 9.7 years. The pharmaceutical care decreased “unnecessary drug therapy” (p < 0.001), identified more “adverse drug reactions” (p = 0.039) and increased the average of percentage of medication administration (p = 0.041). Meanwhile, the standard service decreased “unnecessary drug therapy” (p = 0.016). In this study, the rash was found in 11.97% of the patients with the average onset ± SD of 18.8 ± 17.5 days. Conclusion: The pharmaceutical care decreased “unnecessary drug therapy”, identified more “adverse drug reactions” and increased the average percentage of medication administration. Pharmacists should closely monitor patients who have recently initiated lamotrigine treatment for the development of a drug rash.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Anjali Jayakumar ASA, Shishir Kumar, Sharad Chand, Sophia M. George, Juno J. Joel, Nandakumar UP. Critical analysis of drug related problems among inpatients in the psychiatry department of a tertiary care teaching hospital: A pharmacist led initiative. Clinical Epidemiology and Global Health. 2021;11.
Bell JS, Rosen A, Aslani P, Whitehead P, Chen TF. Developing the role of pharmacists as members of community mental health teams: perspectives of pharmacists and mental health professionals. Res Social Adm Pharm. 2007;3(4):392-409.
Betts T, Goodwin G, Withers RM, Yuen AW. Human safety of lamotrigine. Epilepsia. 1991;32 Suppl 2:S17-21.
Biton V, Shneker BF, Naritoku D, Hammer AE, Vuong A, Caldwell PT, et al. Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials. Clin Drug Investig. 2013;33(5):359-64.
Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63(11):1012–9.
Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008 Mar;10(2):323-33.
Cipolle RJ SL, Morley PC. Pharmaceutical Care Practice: The Patient Centered Approach to Medication Management. 3 ed. New York: McGraw-Hill, Health Professions Division; 2012.
Faught E, Morris G, Jacobson M, French J, Harden C, Montouris G, et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia. 1999;40(8):1135-40.
Giri VP, Giri OP, Khan FA, Kumar N, Kumar A, Haque A. Valproic Acid versus Lamotrigine as First-line Monotherapy in Newly Diagnosed Idiopathic Generalized Tonic -Clonic Seizures in Adults - A Randomized Controlled Trial. J Clin Diagn Res. 2016;10(7):Fc01-4.
GlaxoSmithKline. NC: Highlights of prescribing information: The GSK group of companies. 2016.
Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40(7):985-91.
Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, Resor SR Jr. Predictors of Lamotrigine-associated rash. Epilepsia. 2006 Feb;47(2):318-22.
Hurley SC. Lamotrigine update and its use in mood disorders. Ann Pharmacother. 2002;36(5):860-73.
Kaur S, Dogra A. Toxic epidermal necrolysis due to concomitant use of lamotrigine and valproic Acid. Indian J Dermatol. 2013;58(5):406.
Keely JL. Pharmacist scope of practice. Ann Intern Med. 2002;136(1):79-85.
Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. J Clin Psychiatry. 2006;67(3):400-6.
Kupapan T, Chusakul T, Kanjanasilp J, Sutthiruksa S. Increasing drug adherence by using multimedia and pharmaceutical care for patients with major depressive disorder [independent study]. Mahasara kham: Mahasarakham University; 2014
Ohtahara S, Fujiwara T, Kaneko S. lijima M. Clinical evaluation of lamotrigine with the current recommended dose in overseas—phase III study of lamotrigine in patients with epilepsy treated with valproate. New Rem Clin. 2000;57:1442–1.
Rajesh R, Sudha V, Varma D, Sonika S. Association between Medication Adherence Outcomes and Adverse Drug Reactions to Highly Active Antiretroviral Therapy in Indian Human Immunodeficiency Virus-Positive Patients. J Young Pharm. 2012 Oct;4(4):250-60.
Richens A. Safety of lamotrigine. Epilepsia. 1994;35 Suppl 5:S37-40.
Sakthong P, Jaisue P. Impact of a drug-related patient-reported outcome measure on drug-related problem identification, physicians' acceptance, and clinical and quality of life outcomes: a randomized controlled trial. Int J Clin Pharm. 2022;44(2):320-9.
Salazar-Ospina A, Amariles P, Hincapie-Garcia JA, Gonzalez-Avendano S, Benjumea DM, Faus MJ, et al. Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study. J Manag Care Spec Pharm. 2017; 23(1): 74-84.
Samprasit N and Thavornwattanayong W. Outcome of Pharmaceutical Care in Patients with Psychiatric Disorder: A Systematic Review. Health system research institute (HSRI). 2018;4:590-607.
Shimamura H, Yamada H, Okada N, Uchikura T, Tanaka K, Sasaki T, Itabe H. A Standard Intervention Practice to Promote Appropriate Lamotrigine Therapy by Pharmacists. Biol Pharm Bull. 2018;41(4):465-469.
Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997; 17: 109-12.
Terao T, Ishida A, Kimura T, Yoshida M, Hara T. Assessment of safety and efficacy of lamotrigine over the course of 1-year observation in Japanese patients with bipolar disorder: post-marketing surveillance study report. Neuropsychiatr Dis Treat. 2017; 13: 1441-8.
Wang XQ, Xiong J, Xu WH, Yu SY, Huang XS, Zhang JT, Tian CL, Huang DH, Jia WQ, Lang SY. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure. 2015 Feb;25:52-61.
Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother. 2018;52(9):829-37.
Watanabe Y, Hongo S. Long-term efficacy and safety of lamotrigine for all types of bipolar disorder. Neuropsychiatr Dis Treat. 2017;13:843-54.
Wongpakaran TS, T. Tan-khum, C. Kraivichian, R. Ongarjsakulman, C. Suthisisang. Impact of providing psychiatry specialty pharmacist intervention on reducing drug-related problems among children with autism spectrum disorder related to disruptive behavioural symptoms: A prospective randomized open-label study. Journal of Clinical Pharmacy and Therapeutics. 2017;42:329-36.
Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33(10):1037-42.
Woo YS, Bahk WM, Jon DI, Joo YH, Kim W, Seo JS, Ahn YM, Chung SK, Won SH, Shin YC, Yoon BH, Jung SH, Seok JH, Lee YS, Kim Y, Min KJ. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1147-52.
Yatham LN KS, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD). 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97-170.